Table 2 Results of HTS of CSC with 19 FDA-approved oncology drugs
From: Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening
NSC | Name | % growth | SD (%) | p-value | p-adj | GI 50OVCAR3 (−log10) |
|---|---|---|---|---|---|---|
3053 | Dactinomycin | 8.4 | 3.9 | 1.38E-08 | 1.07E-05 | 8.54 |
24559 | Plicamycin | 10.8 | 3.6 | 9.91E-11 | 7.86E-08 | 7.35 |
67574 | Vincristine | 27.0 | 6.0 | 1.21E-06 | 8.74E-04 | 7.68 |
14229 | Mepacrine | 37.6 | 6.1 | 9.93E-08 | 7.56E-05 | 5.55 |
49842 | Vinblastine | 49.1 | 10.6 | 2.34E-05 | 1.56E-02 | 9.71 |
125066 | Bleomycin | 53.0 | 10.2 | 1.10E-05 | 7.54E-03 | 5.28 |
63878 | Cytarabine | 76.6 | 11.0 | 1.04E-02 | 1 | 5.00 |
105014 | Cladribine | 82.7 | 17.0 | 7.13E-02 | 1 | 4.59 |
755 | Mercaptopurine | 95.2 | 8.4 | 2.83E-01 | 1 | 5.94 |
740 | Methotrexate | 96.7 | 30.8 | 8.38E-01 | 1 | 6.69 |
226080 | Rapamycin | 97.0 | 20.9 | 7.93E-01 | 1 | 8.17 |
296961 | Amifostine | 99.4 | 12.0 | 9.18E-01 | 1 | 3.13 |
85998 | Streptozocin | 103.7 | 28.9 | 8.10E-01 | 1 | 3.14 |
32065 | Hydroxyurea | 107.4 | 14.8 | 2.38E-01 | 1 | 2.92 |
180973 | Tamoxifen | 115.1 | 14.3 | 4.45E-02 | 1 | 5.23 |
750 | Busulfan | 120.6 | 15.9 | 3.65E-02 | 1 | 3.60 |
38721 | Mitotane | 128.2 | 47.6 | 2.68E-01 | 1 | 4.73 |
9706 | Triethylenemelamine | 128.9 | 82.5 | 5.26E-01 | 1 | 4.74 |
45388 | Dacarbazine | 164.3 | 14.2 | 4.46E-04 | 2.68E-01 | 4.25 |